Metabolic consequences of hyperglycemia and insulin resistance

Clinical Cornerstone

Volumn 8, Issue SUPPL. 7, 2007, Pages

  Jellinger, Paul S ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C REACTIVE PROTEIN; CANNABINOID RECEPTOR ANTAGONIST; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; RESISTIN; RIMONABANT; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL DISCOMFORT; ADIPOSE TISSUE; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY ACID TRANSPORT; FIBRINOLYSIS; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER DISEASE; METABOLIC SYNDROME X; MYOCARDIAL DISEASE; NAUSEA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; THROMBOSIS; TISSUE INJURY; WEIGHT GAIN;

BIGUANIDES; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; ENDOCANNABINOIDS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES;

EID: 37349119004     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(07)80019-6     Document Type: Article

References (74)

1. Danaei G., Lawes C., Vander Hoorn S., et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment. Lancet 368 (2006) 1651-1659
2. Lawes C., Parag V., and Bennett D. et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 27 (2004) 2836-2842
3. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005) 1615-1625
4. Cryer P. Hypoglycemia. In: Kasper D., Braunwald E., Fauci A., et al. (Eds). Harrison's Principles of Internal Medicine. 16th ed (2005), McGraw-Hill, New York, NY 2180-2185
5. Yki-Jarvinen H. Nonglycemic effects of insulin. Clin Cornerstone 2003 (2003) S6-S12
6. Eckel R., and Grundy S. Zimmet PZ. The metabolic syndrome. Lancet 365 (2005) 1415-1428
7. Montagnani M., Ravichandran L., Chen H., et al. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells. Mol Endocrinol 16 (2002) 1931-1942
8. Trovati M., and Anfossi G. Insulin, insulin resistance and platelet function: Similarities with insulin effects on cultured vascular smooth muscle cells. Diabetologia 41 (1998) 609-622
9. Juhan-Vague I., and Alessi M. Vague R Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin dependent diabetes mellitus. Ann Med 28 (1996) 371-380
10. Feener E. King GL. Vascular dysfunction in diabetes mellitus. Lancet 350 Suppl 1 (1997) S9-S13
11. McFarlane S., and Banerji M. Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 713-718
12. Guyton J., and Hall J. Insulin, glucagon, and diabetes mellitus. In: Guyton J., and Hall J. (Eds). Textbook of Medical Physiology (2006), Elsevier Saunders, Philadelphia, Pa 961-977
13. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: The link between insulin resistance obesity and diabetes. Trends Immunol 25 (2004) 4-7
14. Furnary A. Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: The Portland Diabetic Project. Endocr Pract 12 Suppl 3 (2006) 22-26
15. Du X., Edelstein D., and Obici S. et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 116 (2006) 1071-1080
16. Kawano H., Motoyama T., and Hirashima O. et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34 (1999) 146-154
17. Miranda P., DeFronzo R., Califf R., and Guyton JR. Metabolic syndrome: Definition, pathophysiology and mechanisms. Am Heart J 149 (2005) 33-45
18. Avramoglu R., and Basciano H. Adeli K. Lipid and lipoprorein dysregulation in insulin resistant states. Clin Chim Acta 368 (2006) 1-19
19. Abrahamson M. A 74-year-old woman with diabetes. N Engl J Med 297 (2007) 196-204
20. Boden G. Laakso M. Lipids and glucose in type 2 diabetes: What is the cause and effect? Diabetes Care 27 (2004) 2253-2259
21. Boden G., Jadali F., and White J. et al. Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest 88 (1991) 960-966
22. Homko C., and Cheung P. Boden G. Effects of free fatty acids on glucose uptake and utilization in healthy women. Diabetes 52 (2003) 487-491
23. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 49 (2000) 27-29
24. Itani S., Ruderman N., Schmieder F., and Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51 (2002) 2005-2011
25. Fonseca V., Desouza C., and Asnani S. Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
26. Meigs J., Mittleman M., Nathan D., et al. Hyper-insulinemia, hyperglycemia and impaired hemostasis: The Framingham Offspring Study. JAMA 283 (2000) 221-228
27. Grundy S., Brewer Jr. H., Cleeman J., et al. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Cirulation 109 (2004) 433-438
28. Shoelson S., and Lee J. Goldfine AB. Inflammation and insulin resistance. J Clin Invest 116 (2006) 1793-1801
29. Hotamisligil G., and Shargill N. Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
30. Feinstein R., Kanety H., and Papa M. et al. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268 (1993) 26055-26058
31. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals. Endocrinol Metab Clin North Am 33 (2004) 283-303
32. Nishikawa T., Edelstein D., and Du X. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
33. Du X., Matsumura T., and Edelstein D. et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112 (2003) 1049-1057
34. Schmidt A., Hori O., and Chen J. et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96 (1995) 1395-1403
35. Schmidt A., Yan S., and Wautier J. Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Cire Res 84 (1999) 489-497
36. Tripathy D., and Mohanty R Dhindsa S. et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52 (2003) 2882-2887
37. Anderson E., and Hoffman RR Balon T. et al. Hyper-insulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87 (1991) 2246-2252
38. Lewis G., Uffelman K., and Szeto L. et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95 (1995) 158-166
39. Brinton E., and Eisenberg S. Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 87 (1991) 536-544
40. de Graaf J., Hendriks J., and Demacker P. Stalenhoef AE Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arterioscler Thromb 13 (1993) 712-719
41. Carroll S. Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med 34 (2004) 371-418
42. Palomo I., Alarcon M., and Moore-Carrasco R. Argiles JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med 18 (2006) 969-974
43. Govindarajan G., Whaley-Connell A., and Mugo M. et al. The cardiometabolic syndrome as a cardiovascular risk factor. Am J Med Sci 330 (2005) 311-318
44. Stump C., and Clark S. Sowers JR. Oxidative stress in insulin-resistant conditions: Cardiovascular implications. Treat Endocrinol 4 (2005) 343-351
45. Inzucchi S., Maggs D., and Spollett G. et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 (1998) 867-872
46. Hundal R., and Inzucchi S. Metformin: New understandings new uses. Drugs 63 (2003) 1879-1894
47. Palamara K., Mogul H., Peterson S., and Frishman W. Obesity: New perspectives and pharmacotherapies. Cardiol Rev 14 (2006) 238-258
48. Rains S., Wilson G., and Richmond W. Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med 82 (1989) 93-94
49. DeFronzo R. Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995) 541-549
50. Reaven G., and Johnston R Hollenbeck C. et al. Combined metformin-sulfonylurea treatment of patients with non-insulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 74 (1992) 1020-1026
51. Giugliano D., De Rosa N., Di Maro G., et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16 (1993) 1387-1390
52. Fonseca V., Rosenstock J., and Patwardhan R. Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 283 (2000) 1695-1702
53. Misbin R. Phenformin-associated lactic acidosis: Pathogenesis and treatment. Ann Intern Med 87 (1977) 591-595
54. Luft D., and Schmulling R. Eggstein M. Lactic acidosis in biguanide-treated diabetics: A review of 330 cases. Diabetologia 14 (1978) 75-87
55. Goodarzi M. Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 7 (2005) 654-665
56. Garg R., Kumbkarni Y., and Aljada A. et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36 (2000) 430-435
57. Aljada A., Garg R., and Ghanim H. et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: Evidence of an antiinflammatory action? J Clin Endocrinol Metab 86 (2001) 3250-3256
58. Ghanim H., Garg R., and Aljada A. et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86 (2001) 1306-1312
59. Fonseca V., Reynolds T., and Hemphill D. et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12 (1998) 181-186
60. Parulkar A., Pendergrass M., and Granda-Ayala R. et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 134 (2001) 61-71
61. Haffner S., Greenberg A., and Weston W. et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Cireulation 106 (2002) 679-684
62. Promrat K., Lutchman G., and Uwaifo G. et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
63. Nissen S. Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 1304-1316
64. Gadde K., and Allison D. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Cireulation 114 (2006) 974-984
65. Matsuda L., Lolait S., and Brownstein M. et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
66. Spanagel R. Weiss E The dopamine hypothesis of reward: Past and current status. Trends Neurosci 22 (1999) 521-527
67. Cohen C., Perrault G., Voltz C., et al. SR141716, a central cannabinoid (CB(1)) receptor antagonist blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 (2002) 451-463
68. Colombo G., Agabio R., Diaz G., et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63 (1998) PL113-PL117
69. Vickers S., Webster L., Wyatt A., et al. Preferential effects of the cannabinoid CB 1 receptor antagonist, SR 141716 on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 167 (2003) 103-111
70. Arnone M., Maruani J., and Chaperon F. et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.Psychopharmacology (Berl) 132 (1997) 104-106
71. Simiand J., Keane M., Keane P., and Soubrie R. SR 141716, a CB 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9 (1998) 179-181
72. Van Gaal L., Rissanen A., Scheen A., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
73. Pi-Sunyer F., Aronne L., Heshmati H., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295 (2006) 761-775
74. Scheen A., Finer N., Hollander P., et al. Efficacy and toterability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet 368 (2006) 1660-1672